Concepedia

Author

Francisco Cristobal Muñoz‐Casares

Hospital Universitario Reina SofíaORCID

Also Known As

F. C. Muñoz-Casares, F.C. Muñoz-Casares, Francisco C. Muñoz-Casares, Francisco C. Muñoz‐Casares, Francisco Cristobal Muñoz-Casares, Francisco Cristobal Muñoz‐Casares, Francisco Cristóbal Muñoz-Casares

25

Publications

675

Citations

12

H-Index

19

Concepts

All Affiliations

Hospital Universitario Reina SofíaInstituto Maimónides de Investigación Biomédica de CórdobaUniversity of Córdoba
FC

About

Francisco Cristobal Muñoz‐Casares is an author at Hospital Universitario Reina Sofía specializing in medicine, surgical oncology, and surgery.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

8

8

313

2

Obstetrics

6

6

277

3

Nephrology

1

1

36

4

Pathology

1

1

12

5

Perioperative Medicine

1

1

24

Francisco Cristobal Muñoz‐Casares

×

11

Publications

560

Citations

11

H-Index

YearCitations

Radical surgery‐peritonectomy and intraoperative intraperitoneal chemotherapy for the treatment of peritoneal carcinomatosis in recurrent or primary ovarian cancer

Sebastián Rufián, Francisco Cristobal Muñoz‐Casares, Javier Briceño,

Journal of Surgical Oncology

2006

120

Melatonin reduces apoptosis and necrosis induced by ischemia/reperfusion injury of the pancreas

Francisco Cristobal Muñoz‐Casares, Javier Briceño, Juan A. Collado,

Journal of Pineal Research

2006

100

The role of hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) in the treatment of peritoneal carcinomatosis in recurrent ovarian cancer

Francisco Cristobal Muñoz‐Casares, Sebastián Rufián, María Jesús Rubio,

Clinical & Translational Oncology

2009

68

Peritonectomy procedures and HIPEC in the treatment of peritoneal carcinomatosis from ovarian cancer: Long-term outcomes and perspectives from a high-volume center

Francisco Cristobal Muñoz‐Casares, Francisco Fernández, Álvaro Arjona‐Sánchez,

European Journal of Surgical Oncology

2015

56

Postoperative Time Course and Utility of Inflammatory Markers in Patients with Ovarian Peritoneal Carcinomatosis Treated with Neoadjuvant Chemotherapy, Cytoreductive Surgery, and HIPEC

Francisco Fernández, Francisco Cristobal Muñoz‐Casares, Álvaro Arjona‐Sánchez,

Annals of Surgical Oncology

2014

47

LC–MS/MS quantitative analysis of paclitaxel and its major metabolites in serum, plasma and tissue from women with ovarian cancer after intraperitoneal chemotherapy

M.A. Fernández-Peralbo, Feliciano Priego‐Capote, M. D. Luque de Castro,

Journal of Pharmaceutical and Biomedical Analysis

2014

40

“Assessment of RIFLE and AKIN criteria to define acute renal dysfunction for HIPEC procedures for ovarian and non ovarian peritoneal malignances”

Álvaro Arjona‐Sánchez, A. Cadenas-Febres, Juan Cabrera-Bermon,

European Journal of Surgical Oncology

2016

36

Neoadjuvant intraperitoneal chemotherapy with paclitaxel for the radical surgical treatment of peritoneal carcinomatosis in ovarian cancer: a prospective pilot study

Francisco Cristobal Muñoz‐Casares, Sebastián Rufián, Álvaro Arjona‐Sánchez,

Cancer Chemotherapy and Pharmacology

2011

30

Outcome of Patients with Aggressive Pseudomyxoma Peritonei Treated by Cytoreductive Surgery and Intraperitoneal Chemotherapy

Álvaro Arjona‐Sánchez, Francisco Cristobal Muñoz‐Casares, Ángela Casado-Adam,

World Journal of Surgery

2013

27

Morbidity and mortality outcomes after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients aged 75 years and over: Spanish group of peritoneal cancer surgery (GECOP) multicenter study

P.A. Cascales-Campos, Víctor López‐López, Francisco Cristobal Muñoz‐Casares,

Surgical Oncology

2016

24

Page 1